Table 1.
Participants’ characteristics by trajectories of days of overall medical cannabis use and days of high-THC medical cannabis use
| Total Sample | Clusters of Overall Medical Cannabis Use |
Clusters of High-THC Medical Cannabis Use |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| N = 99 | Infrequent Use (n=30) | Occasional Use (n=28) | Frequent Use (n=41) | P | Infrequent Use (n=50) | Occasional Use (n=24) | Frequent Use (n=25) | P | |
| Sociodemographic characteristics | |||||||||
| Age, years, mean±SD | 53.1±13.5 | 53.4±14.6 | 51.4±13.5 | 54±12.8 | 0.72 | 55.3±13.3 | 50.5±15.8 | 51.2±10.8 | 0.16 |
| Female gender, n (%) | 62 (62.6) | 17 (56.7) | 20 (71.4) | 25 (61) | 0.49 | 34 (68) | 15 (62.5) | 13 (52) | 0.40 |
| Race/ethnicity, n (%) | 0.004 | 0.03 | |||||||
| Non-Hispanic White | 45 (45.5) | 7 (23.3) | 12 (42.9) | 26 (63.4) | – | 16 (32) | 12 (50) | 17 (68) | – |
| Non-Hispanic Black | 23 (23.2) | 9 (30) | 11 (39.3) | 3 (7.3) | – | 14 (28) | 8 (33.3) | 1 (4) | – |
| Hispanic (any race) | 25 (25.3) | 12 (40) | 4 (14.3) | 9 (22) | – | 16 (32) | 3 (12.5) | 6 (24) | – |
| Non-Hispanic other race | 6 (6.0) | 2 (6.7) | 1 (3.5) | 3 (7.3) | – | 4 (8) | 1 (4.2) | 1 (4) | – |
| Currently employed, n (%) | 22 (22.2) | 3 (10) | 11 (39.3) | 8 (19.5) | 0.02 | 12 (24) | 5 (20.8) | 5 (20) | 0.91 |
| Health insurance, n (%)^ | 0.098 | 0.73 | |||||||
| Public | 72 (72.7) | 26 (86.7) | 19 (67.9) | 27 (65.9) | – | 38 (76) | 16 (66.7) | 18 (72) | – |
| Private | 26 (26.3) | 3 (10) | 9 (32.1) | 14 (34.2) | – | 11 (22) | 8 (33.3) | 7 (28) | – |
| Substance use, n (%) | |||||||||
| Current nonmedical cannabis use | 40 (40.4) | 14 (46.7) | 12 (42.9) | 14 (34.2) | 0.54 | 18 (36) | 11 (45.8) | 11 (44) | 0.66 |
| Cannabis dependence or abusea | 8 (8.1) | 2 (6.7) | 1 (3.6) | 5 (12.2) | 0.41 | 2 (4) | 3 (12.5) | 3 (12) | 0.32 |
| >7 days of opioid use in the past 14 days | 40 (40.4) | 14 (46.7) | 6 (21.4) | 20 (48.8) | 0.053 | 21 (42) | 10 (41.7) | 9 (36) | 0.87 |
| Problematic alcohol useb | 6 (6.1) | 1 (3.3) | 3 (10.7) | 2 (4.9) | 0.46 | 2 (4) | 2 (8.3) | 2 (8) | 0.69 |
| Current tobacco use | 31 (31.3) | 12 (40) | 4 (14.3) | 16 (36.6) | 0.07 | 15 (30) | 5 (20.8) | 11 (44) | 0.21 |
| Pain and mental health | |||||||||
| PEG score,c mean±SD | 7.3±2.0 | 7.6±2.2 | 7.6±1.5 | 6.9±2.1 | 0.20 | 7.3±2.2 | 7.4±1.7 | 7.3±1.9 | 0.92 |
| Moderate or severe anxiety symptoms,d n (%) | 32 (32.3) | 7 (23.3) | 11 (39.3) | 14 (34.2) | 0.41 | 12 (24) | 8 (33.3) | 12 (48) | 0.11 |
| Moderate or severe depression symptoms,e n (%) | 42 (42.4) | 15 (50) | 12 (42.9) | 15 (36.6) | 0.53 | 20 (40) | 9 (37.5) | 13 (52) | 0.52 |
| High PTSD symptoms,f n (%) | 40 (40.4) | 11 (36.7) | 12 (42.9) | 17 (41.5) | 0.88 | 16 (32) | 9 (37.5) | 15 (60) | 0.06 |
| High ADHD symptoms,g n (%) | 45 (45.5) | 13 (43.3) | 13 (46.4) | 19 (46.3) | 0.96 | 22 (44) | 9 (37.5) | 14 (56) | 0.41 |
| Moderate or severe insomnia symptoms,h n (%) | 35 (35.4) | 14 (46.7) | 10 (35.7) | 11 (26.8) | 0.22 | 20 (40) | 5 (20.8) | 10 (40) | 0.23 |
| Clinically relevant pain catastrophizing,i n (%) | 41 (41.4) | 12 (40) | 13 (46.4) | 16 (39) | 0.81 | 21 (42) | 9 (37.5) | 11 (44) | 0.89 |
SD = standard deviation; PEG = Pain, Enjoyment of life, and General activity scale; ADHD = attention deficit-hyperactivity disorder.
Proportions exclude one person who did not have health insurance.
Mini-International Neuropsychiatric Interview [28].
Score >4 for men and >3 on the Alcohol Use Disorders Identification Test [30].
Ref. [21].
Score >10 on the General Anxiety Disorder-7 [24].
Score >10 on the Patient Health Questionnaire-9 [23].
Score >14 on the PTSD CheckList—Civilian Version [25].
Score >14 on the World Health Organization ADHD self-report scale [26].
Score >15 on the Insomnia Severity Index [27].
Score >30 on the Pain Catastrophizing Scale [22].